Cancer drugmaker Turning Point Therapeutics recently filed paperwork calling for a $100 million initial public offering.
Lloyd Sanders, previously with Myriad Genetics, has joined Epic Sciences as CEO.
BIOTECH: ViaCyte Built Up IP, Absorbed Rivals
In 1998, researchers derived stem cells from human embryos for the first time. With the advance came the hope of curing Type 1 diabetes.
CV Sciences is cashing in on rising demand for cannabidiol, or CBD.
PHARMA: Drug Used to Reverse Antiplatelet Activity
PhaseBio’s stock jumped March 18 after the company’s lead drug candidate showed promise in an early-stage clinical study.
A Sharp HealthCare program that delivers palliative care at home captured the 2019 Hearst Prize.
CureMetrix got the U.S. Food and Drug Administration’s blessing to market software that flags which mammograms raise suspicions of breast cancer.
PhaseBio’s stock jumped March 18 after the San Diego-based company’s lead drug candidate showed promise in an early-stage clinical study.
For San Diego life sciences the fourth quarter of 2018 was the strongest of the year from a leasing perspective.
Scripps Research stands to gain a royalty windfall from a drug candidate that slows brain atrophy in patients with multiple sclerosis.